Form 4: Adverum Biotechnologies Director Dawn Svoronos Reports Stock Option Grant

Director Dawn Svoronos reports the grant of stock options in Adverum Biotechnologies.

Summary

• Dawn Svoronos, a director of Adverum Biotechnologies, filed a Form 4 disclosing a transaction involving derivative securities.
• On June 17, 2024, Svoronos was granted a stock option to purchase 10,520 shares of Adverum Biotechnologies common stock at an exercise price of $7.32 per share.
• The options vest on the earlier of June 17, 2025, or the 2025 annual meeting of stockholders, subject to accelerated vesting upon a change of control and continued service with the issuer.
• Svoronos also has a Power of Attorney designating certain officers of Adverum Biotechnologies to act on her behalf in matters related to Section 16 filings.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to executive compensation, indicating a neutral sentiment. It reflects standard corporate governance practices.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is tied to continued service and a potential change of control.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded biotechnology companies.
• The size of the grant (10,520 shares) would need to be compared to grants at similar companies to determine if it is within industry norms.
• Companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director to contribute to the company's success.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates